Immunotherapy combo shows promise against rare sarcomas before surgery
NCT ID NCT03307616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) and radiation before surgery can help shrink tumors in people with two rare types of sarcoma. About 32 adults with these cancers that can be surgically removed will receive the treatment and then have surgery. The goal is to see if this approach improves the tumor's response to treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Blood test may spot hidden sarcoma signals
- Immunotherapy boosts chemo against rare sarcomas?
- Could a breast cancer drug help fight liposarcoma?
- New combo therapy aims to shrink sarcomas
- Focused ultrasound trial for rare sarcoma halted early